AU2002255952A1 - Short bioactive peptides and methods for their use - Google Patents

Short bioactive peptides and methods for their use

Info

Publication number
AU2002255952A1
AU2002255952A1 AU2002255952A AU2002255952A AU2002255952A1 AU 2002255952 A1 AU2002255952 A1 AU 2002255952A1 AU 2002255952 A AU2002255952 A AU 2002255952A AU 2002255952 A AU2002255952 A AU 2002255952A AU 2002255952 A1 AU2002255952 A1 AU 2002255952A1
Authority
AU
Australia
Prior art keywords
methods
bioactive peptides
short bioactive
short
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002255952A
Other languages
English (en)
Inventor
Donald R Owen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helix Biomedix Inc
Original Assignee
Helix Biomedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/820,053 external-priority patent/US6875744B2/en
Application filed by Helix Biomedix Inc filed Critical Helix Biomedix Inc
Publication of AU2002255952A1 publication Critical patent/AU2002255952A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Insects & Arthropods (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2002255952A 2001-03-28 2002-03-28 Short bioactive peptides and methods for their use Abandoned AU2002255952A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27950501P 2001-03-28 2001-03-28
US09/820,053 2001-03-28
US09/820,053 US6875744B2 (en) 2001-03-28 2001-03-28 Short bioactive peptides
US60/279,505 2001-03-28
PCT/US2002/009534 WO2002079408A2 (en) 2001-03-28 2002-03-28 Short bioactive peptides and methods for their use

Publications (1)

Publication Number Publication Date
AU2002255952A1 true AU2002255952A1 (en) 2002-10-15

Family

ID=26959709

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002255952A Abandoned AU2002255952A1 (en) 2001-03-28 2002-03-28 Short bioactive peptides and methods for their use

Country Status (8)

Country Link
US (1) US7381704B2 (enExample)
EP (2) EP1379265A4 (enExample)
JP (2) JP4310107B2 (enExample)
KR (1) KR100891157B1 (enExample)
AU (1) AU2002255952A1 (enExample)
CA (1) CA2441562C (enExample)
ES (1) ES2389285T3 (enExample)
WO (1) WO2002079408A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2521979A1 (en) * 2003-04-09 2004-10-28 University Of Utah Research Foundation Compositions and methods related to production of erythropoietin
JP2005281225A (ja) * 2004-03-30 2005-10-13 Japan Science & Technology Agency 新規塩基性抗菌ペプチド及びその利用
US20090220435A1 (en) * 2005-07-27 2009-09-03 Nastech Pharmaceutical Company Inc. Tight junction modulating peptide components for enhancing mucosal delivery of therapeutic agents
US7601361B2 (en) * 2005-10-03 2009-10-13 E. I. Du Pont De Nemours And Company Process for providing antimicrobial surfaces
JP5173838B2 (ja) 2006-02-13 2013-04-03 アレシア・バイオセラピューティクス・インコーポレーテッド 骨リモデリングのプロセスと関係があるポリヌクレオチドおよびポリペプチド配列
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
KR101552453B1 (ko) * 2006-06-01 2015-09-11 데라퓨틱 펩타이즈, 인코포레이션 중합성 생계면활성제
PL2027152T3 (pl) 2006-06-13 2012-04-30 Helix Biomedix Inc Fragmenty peptydów do indukowania syntezy białek macierzy zewnątrzkomórkowej
KR100742982B1 (ko) * 2006-06-22 2007-07-26 케이맥(주) 초점 타원계측기
EP2125878B1 (en) * 2007-01-05 2013-02-20 Helix Biomedix, Inc. Short bio-active peptides for cellular and immunological modulation
EP2152726B8 (en) * 2007-05-01 2015-02-18 Fundação de Amparo à Pesquisa do Estado de São Paulo - FAPESP Analgesic compounds
PL2205623T3 (pl) 2007-10-29 2016-09-30 Ochronne tetrapeptydy do pielęgnacji skóry
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
EP2168591A1 (en) * 2008-09-24 2010-03-31 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Antimicrobial peptides
US20120270770A1 (en) * 2010-08-03 2012-10-25 Jesse Michael Jaynes Anti-angiogenic peptides and their uses
AU2013293062A1 (en) 2012-07-19 2014-07-24 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
ITBS20120126A1 (it) * 2012-08-01 2014-02-02 Paoli Ambrosi Gianfranco De Composizione antibatterica per uso topico
CN105283198A (zh) * 2013-04-09 2016-01-27 卡勒德·莫希·埃尔丹·伊罗丹 作为恶性肿瘤控制中的单一疗法的新型肽
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
EP3206703B1 (en) * 2014-10-14 2021-05-19 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Peptide for treating pancreatic cancer
CN105061562B (zh) * 2015-09-16 2018-01-12 山东电力中心医院 一种具有抗肺癌作用的寡肽及其应用
US9439917B1 (en) * 2015-12-28 2016-09-13 Shetal Amit Shah Anti-blepharitis compositions and their use
CN109069578A (zh) 2016-02-29 2018-12-21 达纳-法伯癌症研究所股份有限公司 用于治疗感染的钉合的细胞内靶向抗微生物肽
AU2018304230A1 (en) 2017-07-19 2020-02-06 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections
CN112040968B (zh) * 2018-04-30 2024-01-30 欧莱雅 对人肌肉烟碱性乙酰胆碱受体具有高结合亲和力的生物活性肽
KR20210151945A (ko) 2019-04-12 2021-12-14 립타이드 바이오사이언스, 인코포레이티드 대식세포 활성을 조정하기 위한 방법
FR3099060B1 (fr) * 2019-07-26 2022-01-14 Bionuclei Complexe hybride mineral et organique et son utilisation pour le maintien de l’equilibre microbiologique de la peau et/ou d’une composition cosmetique et/ou dermopharmaceutique
TR2023016596A2 (tr) * 2023-12-06 2024-01-22 Karadeniz Teknik Ueniversitesi Teknoloji Transferi Uygulama Ve Arastirma Merkezi Mueduerluegue Anti̇bi̇yoti̇klere alternati̇f yeni̇ ki̇tosan konjuge anti̇mi̇krobi̇yal pepti̇ti̇n geli̇şti̇ri̇lmesi̇
AU2025212440A1 (en) * 2024-01-25 2026-07-02 Lipotrue, S.L. Peptides and cosmetic compositions for use in the treatment of acne and its related skin conditions
CN120209088B (zh) * 2025-03-07 2026-03-03 黄小柯 一种多效蛋白mel3及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4520016A (en) * 1980-06-17 1985-05-28 Kabigen Ab Bacteriolytic proteins
US4355104A (en) 1980-06-17 1982-10-19 Kabigen Ab Bacteriolytic proteins
DE3854476T2 (de) * 1987-07-06 1996-04-04 Univ Louisiana State Inhibierung von eukaryotischen pathogenen und neoplasmen mit lytischen peptiden.
CA1327311C (en) * 1987-07-06 1994-03-01 Jesse M. Jaynes Therapeutic antimicrobial polypeptides, their use and methods for preparation
US5861478A (en) * 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
WO1990012866A1 (en) * 1989-04-10 1990-11-01 Louisiana State University And Agricultural And Mechanical College Lytic peptides, use for growth, infection and cancer
CA2107674A1 (en) * 1991-04-08 1992-10-09 W. Lee Maloy Novel peptide compositions and uses therefor
US5955573A (en) 1993-06-04 1999-09-21 Demegen, Inc. Ubiquitin-lytic peptide fusion gene constructs, protein products deriving therefrom, and methods of making and using same
WO1994028921A1 (en) * 1993-06-04 1994-12-22 Demeter Biotechnologies, Ltd. Method of treating pulmonary disease states with non-naturally occurring amphipathic peptides
US5561107A (en) * 1993-06-04 1996-10-01 Demeter Biotechnologies, Ltd. Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides
AU1086595A (en) * 1993-11-08 1995-05-29 Demeter Biotechnologies, Ltd. Methylated lysine-rich lytic peptides and method of making same by reductive alkylation
US5789542A (en) * 1994-04-22 1998-08-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Amphipathic peptides
IL114697A0 (en) 1994-07-22 1995-11-27 Demeter Biotech Ltd Polypeptides comprising ubiquitin-lytic peptide fusion protein products deriving therefrom their preparation and use
EP0866805A1 (en) * 1995-12-12 1998-09-30 Karolinska Innovations AB PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US6566334B1 (en) * 1997-02-06 2003-05-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Short amphipathic peptides with activity against bacteria and intracellular pathogens
US6635740B1 (en) * 1997-03-27 2003-10-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ligand/lytic peptide compositions and methods of use
US6958212B1 (en) * 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
EP1254167A2 (en) 2000-01-06 2002-11-06 Monsanto Technology LLC Preparation of deallergenized patatin proteins and patatin permutein proteins

Also Published As

Publication number Publication date
WO2002079408A3 (en) 2002-11-28
KR20040002880A (ko) 2004-01-07
JP4310107B2 (ja) 2009-08-05
KR100891157B1 (ko) 2009-04-07
JP4484941B2 (ja) 2010-06-16
CA2441562A1 (en) 2002-10-10
WO2002079408A2 (en) 2002-10-10
HK1135330A1 (en) 2010-06-04
CA2441562C (en) 2013-05-14
JP2005506300A (ja) 2005-03-03
EP1379265A2 (en) 2004-01-14
US20030109452A1 (en) 2003-06-12
JP2009137992A (ja) 2009-06-25
US7381704B2 (en) 2008-06-03
EP2105141A1 (en) 2009-09-30
ES2389285T3 (es) 2012-10-24
EP2105141B1 (en) 2012-08-08
EP1379265A4 (en) 2005-09-14

Similar Documents

Publication Publication Date Title
EP1379265A4 (en) SHORT BIOACTIVE PEPTIDES AND METHODS OF USE
AU2002357643A1 (en) The human mob-5 (il-24) receptors and uses thereof
AU2002326293A1 (en) Human secreted proteins
AU2002321999A1 (en) Human secreted proteins
EP1414848A4 (en) REPLICINE PEPTIDES AND ITS USES
EP1419175A4 (en) PEPTIDES OF REPLIKIN AND THEIR USE
AU2002341828A1 (en) Enhanced proteins and methods for their use
AU2002312373A1 (en) Structural and cytoskeleton-associated proteins
AU2002318186A1 (en) Novel human kielin-like proteins and polynucleotides encoding the same
AU2002320621A1 (en) Structural and cytoskeleton-associated proteins
AU2002354188B2 (en) Novel peptides and medicinal uses thereof
AU2001274923A1 (en) Novel human thrombospondin-like proteins and polynucleotides encoding the same
AU2002360333A1 (en) Human angiomotin-like protein 1
AUPR589701A0 (en) Novel peptide and use thereof
AU2002343516A1 (en) Structural and cytoskeleton-associated proteins
AU2002257630A1 (en) Human mrp5-like protein
AU2003246103A1 (en) Recombinant protein for preventing human chlamydia trachomatis and the uses thereof
AU2001260116A1 (en) Human dcc-like proteins
AU2002341133A1 (en) Modified peptides and their uses
SG2012018057A (en) Replikin peptides and uses thereof
WO2002061044A9 (en) Synthetic peptide and uses for same
AU2002240968A1 (en) Integrin alphaiibbeta3 activating peptides and their use
AU2001270451A1 (en) Memory-enhancing peptides and the use thereof
AU2002328853A1 (en) Carcinoma-related peptides
AU2002230137A1 (en) Novel protein and use thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase